B-cell lymphoma subtypes
Precision analysis to identify and diagnose
Mature aggressive B-cell neoplasms include several specific disease entities such as diffuse large B-cell lymphoma (DLBCL) and primary mediastinal (thymic) large B-cell lymphoma (PMBL). PMBL occurs primarily in the mediastinum and is one of the few B-cell lymphomas with a slightly higher incidence in young women. Due to differences in treatment options, laboratory testing to establish a specific diagnosis is important to selecting the best therapy.
Among our test offerings to detect, diagnose, and differentiate B-cell lymphomas is a first-in-class molecular evaluation to distinguish PMBL from DLBCL that overcomes the challenges of traditional testing approaches. We also offer comprehensive fluorescence in situ hybridization (FISH) test options that enable detection of abnormal genes associated with various chromosome translocations and inversions in DLBCL.
Laboratory testing to establish PMBL diagnosis is important to selecting the best treatment. However, accurate identification using traditional tissue immunohistochemistry (IHC) can be difficult due to the challenge of obtaining adequate tissue from difficult biopsy locations, such as the mediastinal area, and the lack of specific immunophenotype. Histologic features are often ambiguous due to cell distortion from crushed biopsies and subtle differences between PMBL and DLBCL samples. To further confound diagnosis, although PMBL occurs primarily in the mediastinum, it has been reported to occur outside the mediastinum while occurrences of DLBCL have been reported within the mediastinum.
The Lymph3Cx test (Mayo ID: PM3CX) is a qualitative gene expression assay performed on RNA extracted from a biopsied tissue sample with a tumor cell content deemed adequate by pathological evaluation. The assay then measures the expression levels of a panel of genes related to lymphoma biology. Finally, the expression levels are analyzed using a mathematical algorithm to determine the likelihood that the tumor is PMBL or DLBCL with a high degree of confidence when the remaining clinical and pathological factors are considered.
PM3CX | Lymph3CX Assay, Primary Mediastinal Large B-cell Lymphoma and Diffuse Large B-cell Lymphoma, mRNA Gene Expression, NanoString, Tissue*(coming soon)
NOTE: This test is designed to be used on formalin-fixed paraffin-embedded (FFPE) tissue specimens confirmed to be large B-cell lymphoma with at least 60% tumor content. Other sample types may produce unexpected or inaccurate results.
*This testing is currently available only to clients who have received prior authorization. For more information, contact Customer Service at 800-533-1710.
Comprehensive FISH testing, simplified
Genetic abnormalities have emerged as one of the most important prognostic markers in B-cell lymphomas and can aid in diagnosis. Several chromosome abnormalities and variants of these abnormalities have been associated with various lymphoma subtypes.
Our approach to fluorescence in situ hybridization (FISH) testing is designed to simplify the ordering process by providing diagnostic panels that include all appropriate genes.
MALI | MAL Immunostain, Technical Component Only
PATHC | Pathology Consultation
The following FISH probes available at Mayo Clinic are associated with specific B-cell lymphoma subtypes, including: